^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIT exon 9 mutation

    i
    Other names: KIT, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
    Entrez ID:
    3815
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI (NCT01541709)
    Phase 2
    Asan Medical Center
    Active, not recruiting
    Last update posted :
    01/01/2024
    Initiation :
    03/01/2012
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    KIT • ANO1
    |
    KIT mutation • KIT exon 9 mutation
    |
    imatinib
    PDR001 Plus Imatinib for Metastatic or Unresectable GIST (NCT03609424)
    Phase 1/2
    Asan Medical Center
    Completed
    Last update posted :
    01/02/2023
    Initiation :
    02/14/2019
    Primary completion :
    11/11/2021
    Completion :
    11/11/2021
    KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1
    |
    KIT mutation • KIT exon 9 mutation • KIT exon 13 mutation
    |
    imatinib • sunitinib • Stivarga (regorafenib) • spartalizumab (PDR001)
    Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors (ZJGIST-01) (NCT04933669)
    Phase 2
    First Affiliated Hospital of Zhejiang University
    Recruiting
    Last update posted :
    10/12/2021
    Initiation :
    09/07/2021
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    KIT • PDGFRA • ANO1
    |
    KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation
    |
    imatinib
    A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (NCT01874665)
    Phase 2
    Ariad Pharmaceuticals
    Completed
    Last update posted :
    05/18/2018
    Initiation :
    06/05/2013
    Primary completion :
    02/28/2015
    Completion :
    07/31/2016
    KIT
    |
    KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation
    |
    Iclusig (ponatinib)